Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Open accessThe DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Abstract
Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of millions of individuals worldwide. To date, the monoaminergic systems (serotonergic, noradrenergic and dopaminergic) in the brain have received the greatest attention in neurobiological studies of mood disorders, and most therapeutics target these systems. However, there is growing evidence that the glutamatergic system is central to the neurobiology and treatment of these disorders. Here, we review data supporting the involvement of the glutamatergic system in mood-disorder pathophysiology as well as the efficacy of glutamatergic agents in mood disorders. We also discuss exciting new prospects for the development of improved therapeutics for these devastating disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This could lead to astrocyte/microglia imbalance, glutamatergic overproduction and excitotoxic neuronal damage (Sanacora et al., 2008) with impact on synapse functionality.”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, increased glutamate levels has been associated with mechanisms involved in stress and depression, such as neuro-inflammatory process, decreased levels of neurotrophic factors, diminished neurogenesis, and neuroplasticity impairment [116,117].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [117]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, rapidly acting antidepressants were discovered in the glutamatergic system (Berman et al., 2000;Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Several classes of antidepressants as well as SSRIs are known to exert action on the glutamate system by influencing NMDA or AMPA receptor transcription (Sanacora et al., 2008).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2008
The cited source says what the claim attributes to it.
In the citing paper
“Glia also play an important role in regulating the synthesis and reuptake of glutamate and thereby influence synaptic function and morphology16,17.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“Although most patients with mood disorders receive some benefit from available treatment”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationEvidence-based health policy—lessons from the Global Burden of Disease Study
Murray, C. J. L., & Lopez, A. D. (1996) · Science · doi:10.1126/science.274.5288.740 · Cited by 2,178
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“, and is approved for the treatment of moderate to severe Alzheimer's disease, in which it has been shown to enhance cognition and minimize clinical deterioration in patients with Alzheimer's disease, vascular dementia or mixed dementi”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Research works printed but not linked: 1
- Preskorn, S. et al. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Annual Conference of the American Psychological Association (San Francisco, California) 154 (2007).
Cited by
Items 601–700 of 1,000
Chitty, K. M., Kaur, M., Lagopoulos, J., Hickie, I. B., & Hermens, D. F. (2014) · Biological Psychology · doi:10.1016/j.biopsycho.2014.02.013 · Cited by 11
Teneralli, R. E., Kern, D. M., Cepeda, M. S., Gilbert, J. P., & Drevets, W. C. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.04.096 · Cited by 11
Hu, B., Boyle, C. A., & Lei, S. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30535 · Cited by 11
Mechanism of action of antidepressants
Sharma, K., Sundriyal, A., Loshali, A., Agrawal, M., Krishna, C. G., & Singh, Y. P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99855-0.00011-7 · Cited by 11
Pesarico, A. P., Rosa, S. G., Stangherlin, E. C., Mantovani, A. C., Zeni, G. R., & Nogueira, C. W. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.01.013 · Cited by 11
The Future of Psychoneuroimmunology: Promises and Challenges
Halaris, A. E., Bechter, K., Haroon, E., Leonard, B. E., Miller, A. H., Pariante, C. M., & Zunszain, P. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70554-5_15 · Cited by 11
NMDA Antagonists and Their Role in the Management of Bipolar Disorder: a Review
Delfino, R. S., Surjan, J. C., Bandeira, I. D., Braziliano, L., Correia‐Melo, F. S., Del-Porto, J. A., Quarantini, L. C., & Lacerda, A. L. T. (2020) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-020-00201-w · Cited by 11
Yoshino, K., Oda, Y., Kimura, M., Kimura, H., Nangaku, M., Shirayama, Y., & Iyo, M. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05555-3 · Cited by 11
Dalvie, S., Fabbri, C., Ramesar, R., Serretti, A., & Stein, D. J. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9762-1 · Cited by 11
Tsai, G. E. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.03.003 · Cited by 11
Erratum: State-Dependent Partial Occlusion of Cortical LTP-Like Plasticity in Major Depression
Kuhn, M., Mainberger, F., Feige, B., Maier, J. G., Mall, V., Jung, N. H., Reis, J., Klöppel, S., Normann, C., & Nissen, C. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.97 · Cited by 11
Hashimoto, K. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181ace848 · Cited by 11
Shamabadi, A., Ahmadzade, A., Aqamolaei, A., Mortazavi, S. H., Hasanzadeh, A., & Akhondzadeh, S. (2022) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v17i3.9733 · Cited by 10
Zuranolone and its role in treating major depressive disorder: a narrative review
Ali, M., Ullah, I., Diwan, M. N., Aamir, A., Awan, H. A., Durrani, A. W., Qudrat, Q. U., Shoib, S., & Berardis, D. D. (2023) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2022-0042 · Cited by 10
Miklowitz, D. J., & Johnson, S. L. (2017) · Wiley eBooks · doi:10.1002/9781394258949.ch8 · Cited by 10
Searching for New Genetic Risk Factors for Neuropsychiatric Disorders in Expression Databases
de Souza, M. B. R., de Lemos, R. R., da Cunha, J. E. G., Filho, J. L. D. L., & de Oliveira, J. R. M. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9321-5 · Cited by 10
Genomic mapping and cellular expression of human CPG2 transcripts in the SYNE1 gene
Loebrich, S., Rathje, M., Hager, E. R., Ataman, B., Harmin, D. A., Greenberg, M. E., & Nedivi, E. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.12.007 · Cited by 10
Özakman, S., Gören, M. Z., Nurten, A., Tekin, N., Kalaycı, R., & Enginar, N. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-02001-1 · Cited by 10
Glutamate Neurotransmission in Psychotic Disorders and Substance Abuse
Kerner, B. (2009) · The Open Psychiatry Journal · doi:10.2174/1874354400903010001 · Cited by 10
Cycloserine Induced-Psychosis in a 22-Year Old Male Pharmacy Student: A Case Report
Nkporbu, A. K., Oluwaseun, A., Denis, A. D., & Chukwuemeka, S. P. (2016) · American Journal of Psychiatry and Neuroscience · doi:10.11648/j.ajpn.20160401.11 · Cited by 10
Guo, J. P., Zhou, D., Grimm, S. W., & Bui, K. (2014) · Xenobiotica · doi:10.3109/00498254.2014.966175 · Cited by 10
Maksimovic, M., Aitta‐aho, T., & Korpi, E. R. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.10.005 · Cited by 10
The dilemma of treatments for epileptic patients with depression
Yang, Y., Gao, X., & Xu, Y. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.959122 · Cited by 10
Treatment of suicidal depression with ketamine in rapid cycling bipolar disorder
Sampath, H., Sharma, I. L., & Dutta, S. K. (2016) · Asia-Pacific Psychiatry · doi:10.1111/appy.12220 · Cited by 10
Increased spinal pain sensitization in major depressive disorder: A pilot study
Tikàsz, A., Tourjman, V., Chalaye, P., Marchand, S., & Potvin, S. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.10.052 · Cited by 10
Hashimoto, K., & Ishima, T. (2010) · PLoS ONE · doi:10.1371/annotation/afc0a9a2-01c0-4e58-8d69-e0ed4ff953fa · Cited by 10
Effects of Medicinal Plants and Phytochemicals on Schizophrenia
Raju, N. R., Rashmitha, S., -, S. P., Torres, E. A., Kishor, M. R., & Achar, R. R. (2023) · Wiley eBooks · doi:10.1002/9781119794127.ch4 · Cited by 9
Lai, K., Zhang, L., & Xu, J. (2023) · Aquatic Toxicology · doi:10.1016/j.aquatox.2023.106654 · Cited by 9
New perspectives on glutamate receptor antagonists as antidepressants
Chung, C. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0400-8 · Cited by 9
Golubeva, E. A., Lavrov, M. I., Veremeeva, P. N., V’yunova, T. V., Shevchenko, K. V., Topchiy, M. A., Asachenko, A. F., & Palyulin, V. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210293 · Cited by 9
Thalamocortical changes in major depression probed by deconvolution and physiology-based modeling
Kerr, C. C., Kemp, A. H., RENNIE, C. J., & Robinson, P. A. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.11.008 · Cited by 9
The Basic and Clinical Pharmacology of Ketamine
Fourcade, E. W., & Lapidus, K. A. B. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_2 · Cited by 9
Nasru, W. N. W., Razak, A., Yaacob, N. M., & Azman, W. N. W. (2021) · PubMed · Cited by 9
Yu, L., An, C., Jia, L., Li, Y., Chen, Q., Zhen, F., Wang, S., & Wang, M. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.09.071 · Cited by 9
Methoxetamine: A foe or friend?
Botanas, C. J., de la Peña, J. B., Kim, H. J., Lee, Y. S., & Cheong, J. H. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.020 · Cited by 9
Chrovian, C. C., Soyode-Johnson, A., Stenne, B., Pippel, D. J., Schoellerman, J., Lord, B., Needham, A. S., Xia, C., Coe, K. J., Sepassi, K., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02113 · Cited by 9
Troubles affectifs et antidépresseurs : innovations thérapeutiques
Fakra, É., Azorin, J., Adida, M., Fonséca, D. D., Kaladjian, A., & Pringuey, D. (2010) · L Encéphale · doi:10.1016/s0013-7006(10)70055-5 · Cited by 9
Maintenance use of ketamine for treatment-resistant depression: an open-label pilot study.
Barenboim, I., & Lafer, B. (2018) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2017-2380 · Cited by 8
Huang, M., Li, Y., Thomas, A. G., Sharma, A., Liyanage, W., Tichý, T., Tenora, L., Su, Y., Ha, J., Hin, N., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00759 · Cited by 8
Yoshida, M., Hasegawa, S., Taniguchi, M., Mouri, A., Suzuki, C., Yoshimi, A., Mamiya, T., Ozaki, N., & Noda, Y. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109208 · Cited by 8
Zhang, X., Gao, W., Cao, W., Niu, J., Guo, Y., Cui, D., Yu, G., Dou, R., Jiao, Q., Qiu, J., et al. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad059 · Cited by 8
Shen, W., Li, Z., Tao, Y., Zhou, H., Wu, H., Shi, H., Huang, F., & Wu, X. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03637-z · Cited by 8
Ren, H., Wang, Z., Yuan, Y., He, Y., Li, W., Ou, Y., Zhang, S., Chen, S., Li, J., Zeng, Y., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.035 · Cited by 8
Tak1 in the astrocytes of mediobasal hypothalamus regulates anxiety‐like behavior in mice
Zhao, F., Zhang, T., Shen, Q., Yin, K., Wang, Y., & Zhang, G. (2020) · Glia · doi:10.1002/glia.23916 · Cited by 8
Krug, J. T., Klein, A. K., Purvis, E. M., Ayala, K., Mayes, M. S., Collins, L., Fisher, M. P. A., & Ettenberg, A. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.01.003 · Cited by 8
Scotti-Muzzi, E., Chile, T., Vallada, H., Otaduy, M. C. G., & Soeiro‐de‐Souza, M. G. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.04.001 · Cited by 8
Role of glutamate and advantages of combining memantine with a 5HT6 ligand in a model of depression
Abraham, R., Nirogi, R. V. S., & Shinde, A. K. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2013.10.007 · Cited by 8
Cosson, V., Schaedeli‐Stark, F., Arab‐Alameddine, M., Chavanne, C., Guerini, E., Derks, M., & Mallalieu, N. L. (2018) · Clinical and Translational Science · doi:10.1111/cts.12566 · Cited by 7
Trebatická, J., Vatrál, M., Katrenčíková, B., Muchová, J., & Ďuračková, Z. (2025) · Antioxidants · doi:10.3390/antiox14060699 · Cited by 7
Oh, K.-N., Oh, D.-R., Kim, Y., & Kim, S. (2025) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2506.06005 · Cited by 7
Chang, E. H., Carreiro, S. T., Frattini, S. A., & Huerta, P. T. (2019) · Bioelectronic Medicine · doi:10.1186/s42234-019-0022-2 · Cited by 7
Lei, S., Boyle, C. A., & Mastrud, M. R. (2022) · eNeuro · doi:10.1523/eneuro.0120-22.2022 · Cited by 7
Kara, N. Z., Flaisher-Grinberg, S., & Einat, H. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.02.008 · Cited by 7
Bunch, L., Pickering, D. S., Gefflaut, T., Vinatier, V., Hélaine, V., Amir, A., Nielsen, B., & Jensen, A. A. (2009) · ChemMedChem · doi:10.1002/cmdc.200900258 · Cited by 7
Efficacy of different doses of ketamine as a bolus in major depressive disorder.
Kheirkhah, F., Tayyebi, G., Rabiee, S. M., Moghadamnia, A. A., & Bijani, A. (2018) · PubMed Central · doi:10.22088/cjim.9.3.220 · Cited by 7
Sasaki‐Hamada, S., Nakamura, Y., Koizumi, K., Nabeta, R., & Oka, J. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.02.028 · Cited by 7
Counselors’ Neuroscience Conceptualizations of Depression
Field, T. A., Beeson, E. T., Luke, C., Ghoston, M. R., & Golubovic, N. (2019) · Journal of Mental Health Counseling · doi:10.17744/mehc.41.3.05 · Cited by 7
Alese, O. O., Ngoupaye, G. T., Rakgantsho, C., Mkhize, N. V., Zulu, S. S., & Mabandla, M. V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117692 · Cited by 7
Cortiñas‐Sáenz, M., Alonso-Menoyo, M. B., Errando, C. L., Alférez-García, I., & Carricondo-Martínez, M. A. (2012) · Revista Española de Anestesiología y Reanimación · doi:10.1016/j.redar.2012.06.004 · Cited by 7
Herde, A. M., Boss, S. D., He, Y., Schibli, R., Mu, L., & Ametamey, S. M. (2018) · Pharmaceuticals · doi:10.3390/ph11030083 · Cited by 7
Micronutrient Intake and Premenstrual Syndrome
Chocano-Bedoya, P. O. (2011) · ScholarWorks@UMassAmherst (University of Massachusetts Amherst) · doi:10.7275/2387359 · Cited by 7
Shahid, S. S., Grecco, G. G., Atwood, B. K., & Wu, Y. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282756 · Cited by 6
A Review of Treatment Modalities for Comorbid Neuropathic Pain and Depression
Chen, Z., Cheng, T., Yang, H., Gao, Y., & Ma, X. (2025) · Journal of Integrative Neuroscience · doi:10.31083/jin26523 · Cited by 6
McGirr, A., & Berlim, M. T. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3731-y · Cited by 6
Ortiz, D. M., Kim, M., Lee, H. J., Botanas, C. J., Custodio, R. J. P., Sayson, L. V., Campomayor, N. B., Lee, C., Lee, Y. S., Cheong, J. H., et al. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.159 · Cited by 6
Elahinia, A., Hassanpour, S., Asghari, A., & Khaksar, E. (2023) · Iranian Journal of Veterinary Medicine · doi:10.32598/ijvm.17.3.1005263 · Cited by 6
Modulating AMPA Receptors for the Treatment of CNS Disorders
Reuillon, T. D., Ward, S. E., & Beswick, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12654-x · Cited by 6
NMDAR modulators as rapid antidepressants: Converging and distinct signaling mechanisms
Lee, B., Pothula, S., & Duman, R. S. (2020) · Integrative Clinical Medicine · doi:10.15761/icm.1000173 · Cited by 6
Malfunction in GABA and Glutamate as Pathways to Depression: A Review of the Evidence
Sharpley, C. F. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s3481 · Cited by 6
Targeting GluN2B/NO Pathway Ameliorates Social Isolation–Induced Exacerbated Attack Behavior in Mice
Fang, W., Wang, X., Cai, M., Liu, X., Wang, X., & Lu, W. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.700003 · Cited by 6
Rajkowska, G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1056-4_14 · Cited by 6
Potential Novel Therapeutics for Bipolar Disorders
Machado‐Vieira, R., Manji, H. K., & Zarate, C. A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_51 · Cited by 6
Self-citationWang, S., Liu, Y., Wu, Z., Jin, Y., Zhang, T., Yang, Z., & Liu, C. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114559 · Cited by 5
Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders
de Boer, G., de Bie, R. M. A., & Swinnen, B. E. K. S. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240517161444 · Cited by 5
Sperry, S. H., & Lippard, E. (2025) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20240044 · Cited by 5
GluN2D expression is regulated by restraint stress and supports active stress coping bouts
Doyle, M. A., Brown, J. A., & Winder, D. G. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109377 · Cited by 5
Maraone, A., Trebbastoni, A., Vita, A. D., D'Antonio, F., de Lena, C., & Pasquini, M. (2022) · JMIR Research Protocols · doi:10.2196/39223 · Cited by 3
Teopiz, K. M., Lo, H. K. Y., Lakhani, M., Kwan, A. T. H., Lim, P. K., Zhang, M. C., Wong, S., Le, G. H., Swainson, J., Cao, B., et al. (2025) · CNS Spectrums · doi:10.1017/s1092852925100278 · Cited by 5
Alese, O. O., & Mabandla, M. V. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225034 · Cited by 5
Okamoto, H., Onitsuka, T., Kuga, H., Oribe, N., Nakayama, N., Fukushima, S., Nakao, T., & Ueno, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.833896 · Cited by 5
Kangas, E. S., Li, X., Vuoriainen, E., Lindeman, S. M., & Astikainen, P. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16569 · Cited by 5
Zhu, X., Amir, E., Singh, G., Clemons, M. J., & Addison, C. (2014) · Journal of bone oncology · doi:10.1016/j.jbo.2014.01.001 · Cited by 5
Miki, T., Eguchi, M., Kochi, T., Fukunaga, A., Chen, S., Nanri, A., Kabe, I., & Mizoue, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256337 · Cited by 5
Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies
Boff, T. C., Soares, S. J. B., Lima, M. D. M., & Ignácio, Z. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-87480-3_19 · Cited by 5
Qneibi, M., Nassar, S., Bdir, S., & Hidmi, A. (2022) · Cells · doi:10.3390/cells11223608 · Cited by 5
Mapping of glutamate metabolism using 1H FID-MRSI after oral administration of [1-13C]Glc at 9.4 T
Ziegs, T., Ruhm, L., Wright, A. M., & Henning, A. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.119940 · Cited by 5
Making Ketamine Work in the Long Run
Associates, I. P., & Early, T. S. (2014) · International Journal of Transpersonal Studies · doi:10.24972/ijts.2014.33.2.141 · Cited by 5
Metabotropic Glutamate Receptors in Amygdala Functions
Ferraguti, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-56170-7_13 · Cited by 5
Ketamine: A Promising Rapid-Acting Antidepressant
Wilkinson, S. T., Ostroff, R. B., Katz, R. B., & Krystal, J. H. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_16 · Cited by 5
Self-citationde Oliveira, R. L., Voss, G. T., Paltian, J. J., Pinz, M. P., Torres, M. L. C. P., Moreira, M. P., Dilelio, M. C., Silveira, C. C., Wilhelm, E. A., & Luchese, C. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00436-x · Cited by 5
Xu, W., Zang, Y., Shen, Q., Shan, Y., Han, B., Zhou, H., & Lai, X. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146377 · Cited by 5
Nangaku, M., Yoshino, K., Oda, Y., Kimura, M., Kimura, H., Hirose, Y., Shirayama, Y., & Iyo, M. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113092 · Cited by 5
Chitty, K. M., Lagopoulos, J., Hickie, I. B., & Hermens, D. F. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.07.004 · Cited by 5
The inhibition of phosphodiesterase type 5 as a novel target for antidepressant action
Liebenberg, N. (2009) · Cited by 5
Uthaug, M. V. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20200624mu · Cited by 5
Increased forebrain EAAT3 expression confers resilience to chronic stress
Ardiles, N. M., Tapia‐Cuevas, V., Estay, S. F., Alcaino, A., Velásquez, V. B., Sotomayor‐Zárate, R., Chávez, A. E., & Moya, P. R. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16216 · Cited by 4
Zhang, L., Zhou, F., Zhang, L., Peng, L., Guo, C., Luo, C., & Chen, H. (2017) · Chemical Research in Chinese Universities · doi:10.1007/s40242-017-6465-7 · Cited by 4
Talaeı, A., Hoseini, F. F., Mahdavi, M., Salehi, M., Karimani, A., & Afzaljavan, F. (2023) · Iranian Journal of Psychiatry · doi:10.18502/ijps.v18i4.13627 · Cited by 4
The role of glutamic acid-modified silica nanoparticles in promoting brain health
Hamdi, E., Hidouri, S., Muñiz‐González, A., Marcos, A., Venero, C., Amara, S., & Landoulsi, A. (2024) · Advances in Redox Research · doi:10.1016/j.arres.2024.100095 · Cited by 4
Rodrigues‐Ribeiro, L., Resende, B. L., Dias, M. L. P., Lopes, M. R., de Barros, L. L. M., Moraes, M. A., Verano‐Braga, T., & Souza, B. R. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-50624-6_6 · Cited by 4
Metadata
- Authors
- Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K.
- Affiliations
- Yale University (US)
- National Institutes of Health (US)
- Corresponding author
- Manji, Husseini K.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-05
- Volume
- 7
- Issue
- 5
- Pages
- 426-437
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC2715836
- OpenAlex
- W2074907255
- Cited by
- 894
- References
- 186
- Citations by year
- 2026: 17 · 2025: 29 · 2024: 33 · 2023: 44 · 2022: 36 · 2021: 44 · 2020: 56 · 2019: 43 · 2018: 40 · 2017: 50 · 2016: 63 · 2015: 70 · 2014: 59 · 2013: 56 · 2012: 68
- FWCI
- 6.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (K02MH076222, Z01MH002828, Z01MH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- glutamatergic system, mood disorders, antidepressants, neuroplasticity, glutamatergic agents, monoaminergic systems, rapid-acting antidepressants, drug development
- MeSH terms
- Animals, Glutamates, Humans, Psychotropic Drugs, Excitatory Amino Acid Antagonists, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.